Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael et al. · New England Journal of Medicine · 2020 · 3.5K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Haibo Zhang, Josef Penninger, Yimin Li et al. · Intensive Care Medicine · 2020 · 2.8K citations · Full text

Medicine, Infectious Diseases, Pharmacology +10

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Shuai Xia, Meiqin Liu, Chao Wang et al. · Cell Research · 2020 · 1.4K citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16